Pathology of Cardiac Allograft Rejection. 1: Vascular (Microvascular)

  • E. H. Hammond


Pathologic descriptions of allograft rejection of all solid organs have long recognized vascular involvement in the rejection process. Renal allografts, the earliest allografts to be studied. commonly display vasculitis involving the arteries and arterioles of the kidney cortex with or without cellular infiltrates invading tubules[1]–[3]. This vascular inflammatory process, often termed acute vascular rejection, is frequently associated with allograft loss in spite of increased immunosuppressive therapy[2],[3]. Similarly, arteritis has been identified in cardiac allografts on endomyocardial biopsy, and has been associated with poor allograft survival[4],[5].


Allograft Rejection Cardiac Allograft Heart Lung Transplant Hyperacute Rejection Myocyte Necrosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jeannet M, Pinn V, Flax M, Winn HJ, Russell PS. Humoral antibodies in renal allotransplantation in man. N Engl J Med. 1970;282:111.PubMedCrossRefGoogle Scholar
  2. 2.
    Farnsworlh A, Hall BM, Ng ABP et al. Renal biopsy morphology in renal transplantation. Am J Surg Pathol. 1984:8:243.CrossRefGoogle Scholar
  3. 3.
    Salmela KT, von Willebrand EO, Kyllonen LEJ. Aeute vaseular rejection in renal transplantation-diagnosis and outcome. Transplantation. 1992:54:858.PubMedCrossRefGoogle Scholar
  4. 4.
    Herskowitz A, Soule LM, Ueda K et al. Arteriolar vaseulilis on endomyocardial biopsy: a histologie predietor of poor outcome and cyelosporin-treated heart transplant recipients. J Heart Transplant. 1987;6:127.PubMedGoogle Scholar
  5. 5.
    Smith SH, Kirklin JK, Geer JC, Caullield JB, MeGiftin DC. Arterius and cardiac rejection after transplantation. Am J Cardiol. 1987:59:1171.PubMedCrossRefGoogle Scholar
  6. 6.
    Butcher EC. The regulation of lymphocyte traffic. Curr Top Microbiol Immunol. 1986:128:85.PubMedGoogle Scholar
  7. 7.
    Berg EL, Goldstein LA, Jutila MA et al. Homing receptors and vascular addressins: cell adhesion molecules that direct lymphocyte migration. Immunol Rev. 1989;108:5.PubMedCrossRefGoogle Scholar
  8. 8.
    Forbes RDC, Guttman RD, Gomersall M, Hibberd J. A controlled serial ultra-structural tracer study of first set cardiac allograft rejection in the rat. Am J Pathol. 1983:111:184.PubMedGoogle Scholar
  9. 9.
    Leszcynski D, Laszcyska M, Halttunen J, Hayry P. Renal target structures in acute allograft rejection: a histochemical study. Kidney Int. 1987;31:1311.CrossRefGoogle Scholar
  10. 10.
    Dvorak HF, Mihm MC, Dvorak AM et al. Rejection of lirst set skin allografts in man: the microvasculature is the critical target of the immune response. J Exp Med 1979:150:322.PubMedCrossRefGoogle Scholar
  11. 11.
    Snover DC, Freese DK, Sharp HL et al. Liver allograft rejection: an analysis of the use of biopsy in determining outcome of rejection. Am J Surg Pathol. 1987:11:1.PubMedCrossRefGoogle Scholar
  12. 12.
    Stewart S. Pathology of lung transplantation. Semin Diagnost Pathol. 1992:9:210.Google Scholar
  13. 13.
    Hammond EH, Yowell RL, Nunoda S et al. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J Heart Transplant. 1989:8:430.PubMedGoogle Scholar
  14. 14.
    Hammond EH, Yowell RL, Price GD et al. Vascular rejection and its relationship to allograft coronary artery disease. J Heart Transplant. 1992:11:S111.Google Scholar
  15. 15.
    Faulk WP, Labarrere CA, Pitts, D, Halbrook H. Laboratory clinical corrctates of time-associated lesions in the vascular immunopathology of human cardiac allografts. J Heart Lung Transplant. 1993:12:S125.PubMedGoogle Scholar
  16. 16.
    Hammond EH, Hansen J, Spencer LS et al. Vascular rejection in cardiac transplantation: histologic, immunopafhologic. and ultrastructural features. Cardiovasc Pathol. 1993:2:21.CrossRefGoogle Scholar
  17. 17.
    Platt JL, Fischct RJ, Matas AJ et al. Immunopathology of hyperacule xenografl rejection in a swine-to-primate modct. Transplantation. 1991;52:214.PubMedCrossRefGoogle Scholar
  18. 18.
    Leventhal JR, Sakiyalak P, Witson J et al. The synergistic effect of combined antibody and complement depletion on discordant cardiac xenograft survival in non-human primates. Transplantation. 1993:57:974.Google Scholar
  19. 19.
    Rose AG Kobayashi T, Kosanke S, While DJG, Cooper DKC. Histopathology of dctayed vascular (humoral) rejection in C3-depleted discordant (pig-to-baboon) cardiac xenografts treated with cobra venom factor-prominent role of venular thrombosis. J Heart Lung Transplant. 1995;14:S72 (abstract).Google Scholar
  20. 20.
    Leventhal JR, Matas AJ, Sun LH et al. The immunopathology of cardiac xenograft rejection in the guinea pig-to-rat modct. Transplantation. 1993;56:1.PubMedCrossRefGoogle Scholar
  21. 21.
    Woodley SL, Renlund DG, O’Connctl JB, Brislow MR. Immunosuppression following cardiac transplantation. Cardiol Clin. 1990:8:83.PubMedGoogle Scholar
  22. 22.
    Renlund DG, O’Connctl JB, Gilbert HM. A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocytc globulin-based rejection prophylaxis in cardiac transplantation. Transplantation. 1989:47:599.PubMedCrossRefGoogle Scholar
  23. 23.
    Ensley RD, Hammond EH, Renlund DG et al. Clinical manifestations of vascular rejection in cardiac transplantation. Transplant Proc. 1991:23:1130.PubMedGoogle Scholar
  24. 24.
    Marboe CC, Schierman SW, Rose E et al. Characterization of mononuclear cell infiltrates in human cardiac allografts. Transplant Proc. 1984:16:1598.PubMedGoogle Scholar
  25. 25.
    Colvin RB. Diagnostic use in transplantation, clinical applications of monoclonal antibodies in renal allograft biopsies. Am J Kidney Dis. 1988:11:126.PubMedGoogle Scholar
  26. 26.
    Bishop AG, Hall BM, Duggin GG et al. Immunopathology of renal allograft rejection analyzed with monoclonal antibodies to mononuclear cell markers. Kidney Int. 1986:29:708.PubMedCrossRefGoogle Scholar
  27. 27.
    Bishop GA, Waugh JA, Landers DV et al. Microvascular destruction in renal transplant rejection. Transplantation. 1989;48:408.PubMedCrossRefGoogle Scholar
  28. 28.
    Hayry P, Renkoncn R, Leszcznski D et al. Local events in graft rejection. Transplant Proc. 1989:21:3716.PubMedGoogle Scholar
  29. 29.
    Faulk WP, Laberrerc CA, Antithrombin-III in normal and transplanted human hearts: indications of vascular disease. Scmin Hematol. 1994:31:1.Google Scholar
  30. 30.
    Labarrere CA, Pitts D, Halbrook H, Faulk WP, Tissue plasminogen activator, plasminogen activator inhibitor-1, and fibrin as indexes of clinical course in cardiac allograft recipients: an immunocytochemical study. Circulation. 1994:89:1599.PubMedGoogle Scholar
  31. 31.
    Lones MA, Harasty D, Miller JM et al. Humoral rejection in cardiac transplant biopsies. Mod Pathol.1994:7:29A.Google Scholar
  32. 32.
    Hook S, Caple JF, McMahon JT, Myles JL, Ratliff NB. Endothclial changes associated with acute vascular rejection (AVR) in human cardiac transplants. Mod Pathol. 1994:7:29A.Google Scholar
  33. 33.
    Ratliff NB, McMahon JT. Activation of intravascular macrophages is a feature of acute vascular rejection (AVR) in human cardiac transplants. Mod Pathol. 1994:7:31A.Google Scholar
  34. 34.
    Loy TS, Bulatao IS, Grant VD et al. Immunoslal.ning of cardiac biopsy specimens in the diagnosis of acute vascular (humoral) rejection: a control study. J Heart Lung Transplant. 1993;12:736.PubMedGoogle Scholar
  35. 35.
    Rand JH, Wu XX, Potter BJ et al. Co-localization of von Willebrand factor and type VI collagen in human vascular subendothctium. Am J Pathol. 1993:142:843.PubMedGoogle Scholar
  36. 36.
    Suster S, Wong TY. On the discriminatory value of anti-HPCA-1 (CD-34) in the differential diagnosis of benign and malignant cutaneous vascular proliferations. Am J Dermatopathol. 1994:16:355.PubMedCrossRefGoogle Scholar
  37. 37.
    Tipping PG, Davenport P, Gallicchio M et al. Atheromatous plaque macrophages produce plasminogen activator inhibitor type-1 and stimulate its production by endothctial cells and vascular smooth muscle cells. Am J Pathol. 1993;143:875.PubMedGoogle Scholar
  38. 38.
    Hammond EH, Hansen LK, Spencer LS et al. Immunofluorescence of endomyocardial biopsy specimens: methods and interpretation. J Heart Lung Transplant. 1993;12:S113.PubMedGoogle Scholar
  39. 39.
    Sell KW, Talaat T, Wang YC et al. Studies of major histocompatibility complex class 1/11 expression on sequential human heart biopsy specimens after transplantion. J Heart Transplant. 1988;7:407.PubMedGoogle Scholar
  40. 40.
    Wijngaard PLJ, Tuijnman WB, Meyling FHJ et al. Endomyocardial biopsies after heart transplantation. The presence of markers indicative of activation. Transplantation. 1993:55:103.PubMedCrossRefGoogle Scholar
  41. 41.
    Gassel AM, Hansmann ML, Radzun HJ, Weyland M. Human cardiac allograft rejection. Corrctation of grading with expression of different monocyte/macrophage markers. Am J Clin. Pathol. 1990;94:274.PubMedGoogle Scholar
  42. 42.
    Briscoe DM, Yeung AC, Schoen Et et al. Predictive value of inducible endothctial cell adhesion molecule expression for acute rejection of human cardiac allografts. Transplantation. 1995:59:204.PubMedCrossRefGoogle Scholar
  43. 43.
    Lemstrom K, Koskinen P, Hayry P. Induction of adhesion molecules on the endothelia of rejecting cardiac allografts. J Heart Lung Transplant. 1995:14:205.PubMedGoogle Scholar
  44. 44.
    Hosenpud JD, Shipley GD, Morris TE et al. The modulation of human aortic endothctial cell ICAM-I expression by serum contal.ning high tilers of anti-HLA antibodies. Transplantation. 1993;55:405.PubMedGoogle Scholar
  45. 45.
    Deng MC, Bett S, Huic P. Cardiac allograft vascular disease: relationship to microvascular cell surface markers and inflammatory cell phenotype on endomyocardial biopsy. Circulation. 1995:91:1647.PubMedGoogle Scholar
  46. 46.
    Boiling SF, Kunket SL, Lin H. Prolongation of cardiac allografl survival in rats by anti-TNF and cyclosporin combination therapy. Transplantation. 1992:53:283.CrossRefGoogle Scholar
  47. 47.
    Imigawa DK, Millis JM, Olthoff KM et al. The role of tumor necrosis factor in allograft rejection: II. Evidence that antibody therapy agal.nst tumor necrosis factor alpha and lymphotoxin enhances cardiac allograft survival in rats. Transplantation. 1990:50:219.CrossRefGoogle Scholar
  48. 48.
    Sadahiro M, McDonald TO, Allen MD. Reduction in cellular and vascular rejection by blocking leukocyte adhesion molecule receptors. Am J Pathol. 1993:142:675.PubMedGoogle Scholar
  49. 49.
    Jordan SC, Czer L, Toyoda M. Serum cytokine levcts in heart allograft recipients: corrctation with findings on endomyocardial biopsy. J Heart Lung Transplant. 1993;12:333.PubMedGoogle Scholar
  50. 50.
    Morgan CJ, Petletier RP, Hemadez CJ et al. Alloanligen dependent endothctial phenotype and lymphokine mRNA expression in rejecting murine cardiac allografts. Transplantation. 1993:55:919.PubMedCrossRefGoogle Scholar
  51. 51.
    Billingham ME, Cary NRB, Hammond ME et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. J Heart Transplant. 1990:9:587.PubMedGoogle Scholar
  52. 52.
    Billingham ME, Berry GJ, Jagdish B et al. A modified working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant, in preparation, 1996.Google Scholar
  53. 53.
    Breisblatt WM, Schulman DS, Stein K et al. Hemodynamic response to OKT3 in orthotopic heart transplant recipients: evidence of reversible myocardial dysfunction. J Heart Lung Transplant. 1991:10:359.PubMedGoogle Scholar
  54. 54.
    Abramowicz D, Schandene L, Goldman M et al. Rctease of tumor necrosis factor. interleukin-2. and gamma-interfcron in scrum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation. 1989;47:606.PubMedCrossRefGoogle Scholar
  55. 55.
    Cotran RS. New roles for the endothctium in inflammation and immunity. Am J Pathol. 1987;129:407.PubMedGoogle Scholar
  56. 56.
    Cotran RS. Pober JS. Gimbrone MA et al. Endolhctial activation during inlerleukin 2 immunoiherapy: a possible mechanism for the vascular leak syndrome. J Immunol. 1987;139:1883.Google Scholar
  57. 57.
    Pober JS. Cytokine-mediated activation of vascular endothctium. Am J Pathol. 1988:133:426.PubMedGoogle Scholar
  58. 58.
    Pober JS, Collins T, Gimbrone MA et al. Inducible expression of class II major histocompatibility complex antigens and the immunogenicity of vascular endothctium. Transplantation. 1986;41:141.PubMedCrossRefGoogle Scholar
  59. 59.
    Miller LW, Wesp A, Jennison SH et al Vascular rejection in heart transplant recipients. J Heart Lung Transplant. 1993;12.S147.PubMedGoogle Scholar
  60. 60.
    Heroux AL, Costanzo-Nordin MR, Radvany R et al. The enigma of acute allografl dysfunction without cellular rejection: role of humoral alloimmunity. J Heart Lung Transplant. 1993;12:S91.Google Scholar
  61. 61.
    Carlquist JF, Hammond EH, Yowell RL et al. Corrctation between class II antigen (DR) expression and interlcukin 2 induced lymphocyte proliferation during acute cardiac allograft rejection. Transplantation. 1990;50:582.PubMedCrossRefGoogle Scholar
  62. 62.
    Gaudin PB, Rayburn BK, Hutchins GM. Peritransplant injury to the myocardium associated with the devctopment of acccterated arteriosclerosis in heart transplant recipients. Am J Surg Pathol. 1994:18:338.PubMedCrossRefGoogle Scholar
  63. 63.
    Zehr KJ, Herskowitz A, Lee PC et al. Neutrophil adhesion inhibition prolongs survival of cardiac allografts with hypcracute rejection. J Heart Lung Transplant. 1993;12:837.PubMedGoogle Scholar
  64. 64.
    Trento A, Hardesly RL, Griffith BP et al. Role of the antibody of vascular endothctial cells in hyperacute rejection in patients undergoing cardiac transplantation. J Thorac Cardiovasc Surg. 1988:95:37.PubMedGoogle Scholar
  65. 65.
    Loy TS, Demmy T. Interobserver variability in the Diagnosis of Cardiac Rejection. Mod Pathol. 1995;8:29A.Google Scholar
  66. 66.
    Olsen SL, Wagoner LE, Hammond EH et al. Vascular rejection in heart transplantation: clinical corrctation, treatment options, and future considerations. J Heart Lung Transplant. 1993;12:S1135.Google Scholar
  67. 67.
    Gill EA, Borrego C, Bray BE et al. Left ventricular mass increases during cardiac allograft vascular rejection. J Am Coll Cardiol. 1995;25:922.PubMedCrossRefGoogle Scholar
  68. 68.
    Marboe CC. Cardiac transplant vasculopathy. In: Hammond EH, editor. Solid organ transplantation pathology Philadctphia. PA: Saunders; 1994:111.Google Scholar
  69. 69.
    Neish AS, Loh E, Schoen FJ. Myocardial changes in cardiac transplant-associated coronary arteriosclerosis: potential for timcty diagnosis. J Am Coll Cardiol. 1992;19:586.PubMedCrossRefGoogle Scholar
  70. 70.
    Hammond EH, Yowell RL. Ultrastructural findings in cardiac transplant recipients. Ultrastruct Pathol. 1994;18:213.PubMedGoogle Scholar
  71. 71.
    Vaughan JH, Barnett EV, Leadley PJ. Serum sickness: evidence in man of antigen-antibody complexes and free light chal.ns in the circulation during the acute reaction. Ann Intern Med. 1967;67:596.PubMedGoogle Scholar
  72. 72.
    Lawley TJ, Bictory L, Gascon P. A prospective clinical and immunologie analysis of patients with serum sickness. N Engl J Med. 1984;311:1407.PubMedCrossRefGoogle Scholar
  73. 73.
    Andres G, Brcnljens JR, Caldwell PRB et al. Biology of disease: formation of immune deposits and disease. Lab Invest. 1986:55:510.PubMedGoogle Scholar
  74. 74.
    Suthanthiran M, Fotino M, Riggio RR et al. OKT3 associated adverse reactions: mechanistic basis and therapeutic options. Am J Kidney Dis. 1989;14:39.PubMedGoogle Scholar
  75. 75.
    Jaffers GJ, Fuller TC, Cusimi B et al. Monoclonal antibody therapy: anti-idiotypic and non anti-idiotypic to OKT3 arising despite intense immunosuppression. Transplantation. 1986;41:572.PubMedCrossRefGoogle Scholar
  76. 76.
    Hammond EH, Wittwer CT, Greenwood J et al. Relationship of OKT3 sensitization and vascular rejection in cardiac transplant patients receiving OKT3 rejection prophylaxis. Transplantation. 1990;50:776.PubMedCrossRefGoogle Scholar
  77. 77.
    Wiltwer CT, Knape WA, Bristow MR et al. Quantitative flow cytometric plasma OKT3 assay: potential application in cardiac transplantation. Transplantation. 1989:48:533.CrossRefGoogle Scholar
  78. 78.
    Hammond E, Yowell R, Greenwood J et al. Monitoring of patients for OKT3 sensilization prevents adverse outcome. Transplantation. 1993;55:1061.PubMedCrossRefGoogle Scholar
  79. 79.
    Pober JS, Cotran RS. The role of endothctial cells in inflammation. Transplantation. 1990:50:537.PubMedCrossRefGoogle Scholar
  80. 80.
    Cines DB, Lyss AP, Bina M et al. Fe and C3 receptors induced by herpes simplex virus on cultured human endothctial cells. J Clin Invest. 1982:69:123.PubMedCrossRefGoogle Scholar
  81. 81.
    Braquet P, Hosford D, Braquet M et al. Role of cylokines and platctet activating factor in microvascular immune injury. Int Arch Allergy Appl Immunol. 1989;88:88.PubMedGoogle Scholar
  82. 82.
    Shaddy RE, Prescott SM, McIntyre TM, Zimmerman GA. Role of endothctial cells in transplant rejection. In: Hammond EH. editor. Solid organ transplantation pathology. Philadctphia, PA: Saunders. 1994:35.Google Scholar
  83. 83.
    Miltenburg AM, Meijer-Paape ME, Weening JJ et al. Induction of antibody-dependent cellular cytotoxicity agal.nst endothctial cells by renal transplantation. Transplantation. 1989;48:681.PubMedCrossRefGoogle Scholar
  84. 84.
    Caillat-Zucman. S, Blumenlctd N, Legendre C et al. The OKT3 immunosuppressive effect: in situ modulation al. human graft infiltrating T cells. Transplantation. 1990:49:156.PubMedCrossRefGoogle Scholar
  85. 85.
    Chatenoud I., Fexran C, Reuler A et al. Systemic reaction to the monoclonal antibody OKT3 in relation to serum levcts of tumor necrosis factor and interferon gamma. N Engl J. Med. 1989:320:1420.PubMedCrossRefGoogle Scholar
  86. 86.
    Charpentier B, Hiesse C, Lantz O et al Evidence that antihuman tumor necrosis factor monoclonal antibody prevents OKT3 induced acute syndrome. Transplantation. 1992:54:997.PubMedCrossRefGoogle Scholar
  87. 87.
    Oluwole SF, Tezuka K, Wastie T et al. Humoral immunity in allngraft rejection. Transplantation. 1989;48:751.PubMedCrossRefGoogle Scholar
  88. 88.
    Mannik M. Mechanisms of tissue deposition of immune complexes. J Rheumatol. 1987:13:35.Google Scholar
  89. 89.
    Martin S, Dyer PA, Mallick NP et al. Post-transplanl anti-donor lymphocytotoxic antibody production in relation to graft outcome. Transplantation. 1991;51:1303.PubMedCrossRefGoogle Scholar
  90. 90.
    Ma H, Hammond EH, Taylor DO, Yowell RL, Renlund D. Relationship of duration ol OKT3 induction to incidence of vascular rejection in cardiac transplant recipients Circulation. Transplantation, 1996. in press.Google Scholar
  91. 91.
    Pizarro TT, Malinowska K, Kovacs EJ et al. Induction of TNFa and TNFh gene expression in rat cardiac transplants during allografl rejection. Transplantation 1993:56:399.PubMedCrossRefGoogle Scholar
  92. 92.
    Maury CPJ, Teppo AM. Ralised serum levcts of cacheetin tumor necrosis factor a in renal allograft rejection. J Exp Med. 1987:166:1132.PubMedCrossRefGoogle Scholar
  93. 93.
    Chollet-Martin S, Depoix JP, Hvass U et al. Raised plasma levcts of tumor necrosis factor in heart allograft rejection. Transplant Proc. 1990:22:283.PubMedGoogle Scholar
  94. 94.
    Dvorak HF, Galli SJ, Dvorak AM. Cellular and vascular manifestations of cell-mediated immunity. Hum Pathol. 1986;17:122.PubMedCrossRefGoogle Scholar
  95. 95.
    Mason DW, Morris PJ. Effector mechanisms in allograft rejection. Annu Rev Immunol. 1986:4:119.PubMedCrossRefGoogle Scholar
  96. 96.
    Hall BM. Cctlular infiltrates in allografts. Transplant Proc. 1987;19:50.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • E. H. Hammond

There are no affiliations available

Personalised recommendations